Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Legend Biotech ( (LEGN) ) has provided an announcement.
On November 12, 2025, Legend Biotech reported its unaudited financial results for the third quarter of 2025, highlighting significant growth in CARVYKTI® sales, with net trade sales reaching approximately $524 million. The company also announced regulatory updates, including FDA and European Commission label updates for CARVYKTI® to reflect its overall survival benefit. Legend Biotech has treated over 9,000 patients to date and initiated commercial production at its Tech Lane facility in Belgium. Financially, the company reported a net loss of $39.7 million for the quarter, a significant improvement from the $125.3 million loss in the same period of 2024. The company holds approximately $1.0 billion in cash and equivalents, providing a financial runway beyond 2026, with expectations of achieving company-wide profitability in 2026.
The most recent analyst rating on (LEGN) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s overall stock score is driven by its financial performance challenges, particularly in profitability and cash flow, which weigh heavily on the score. Despite these issues, the positive sentiment from the recent earnings call, highlighting significant sales growth and strategic advancements, provides a counterbalance. Technical indicators suggest a bearish trend, and valuation metrics are unattractive due to negative earnings. The absence of corporate events does not impact the score.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation is a global leader in cell therapy, primarily focused on developing and marketing CAR-T cell therapies. Its flagship product, CARVYKTI®, is a one-time treatment for relapsed or refractory multiple myeloma, developed in collaboration with Johnson & Johnson. The company is headquartered in Somerset, New Jersey, and is expanding its global commercial footprint with operations in multiple markets worldwide.
Average Trading Volume: 1,189,281
Technical Sentiment Signal: Sell
Current Market Cap: $5.83B
See more insights into LEGN stock on TipRanks’ Stock Analysis page.